Nanolek localizes production of active pharmaceutical substituents of HPV vaccine


The Expert Council of the Industrial Development Fund approved a loan for Nanolek on Priority Projects program, according to the press center of the IDF.

Nanolek, which is based in the Kirov region, will use the loan of 2 billion rubles to localize the production of active pharmaceutical substances for a vaccine against human papilloma virus, as well as for a monoclonal antibody for the treatment of non-Hodgkins lymphoma, chronic lympholeukosis, and some other diseases. If necessary, the production capacity will allow to cover the annual needs of the Russian market for these drugs.

It was earlier reported that Nanolek intends to start producing CoviVac, a vaccine against coronavirus infection developed by Chumakov Research Institute in November. Clinical trials of the combined coronavirus and influenza vaccine are due to begin in a year and a half.